hemophilia

Apr 07, 2025

Sanofi’s Qfitlia Enters the Hemophilia Market—What Sets It Apart?

Apr 01, 2025

Sanofi’s Qfitlia Becomes First FDA-Approved Therapy for Hemophilia A or B; FDA Approves AstraZeneca’s IMFINZI as First Perioperative Immunotherapy for Bladder Cancer; Beam Therapeutics’ BEAM-302 for AATD Receives FDA Clearance; AstraZeneca’s CALQUENCE Combo Greenlit in EU for Mantle Cell Lymphoma; Ionis’ WAINZUA Wins EU Approval for Hereditary Transthyretin Amyloidosis

Nov 21, 2022

RNA Interference: New Class of Drugs In The Fight Against Disease

Jul 12, 2022

Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200

Jun 28, 2022

Ipsen to Buy Epizyme; BioMarin’s Gene Therapy for Hemophilia; AbbVie’s Qulipta for Chronic Migraine; FDA Approves Breyanzi for R/R LBCL; NDA Filed for Elacestrant in ER+/HER2- Breast Cancer; EU Approval to Enhertu for Breast Cancer; FDA Approves Novartis’ BRAF-positive Tumor Combination; GSK’s Hepatitis B Vaccine, Bepirovirsen

Mar 21, 2022

Role of Mobile Technology in Hemophilia Management

Nov 08, 2021

The Evolved Gene Therapy for Hemophilia

Mar 17, 2021

Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market?

Mar 15, 2021

Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere?

Mar 08, 2021

A Royal Disease: Hemophilia

Newsletter/Whitepaper